Print Page   |   Sign In   |   Join
HOD Feedback for Pennsylvania ASHP Members
1
| 2
>
>|
Forum Actions

Topics   Replies Score Author Latest Post
March vHOD COT 5: Pharmacist's Leadership Role in Anticoagulation Therapy M 0 W. O'Hara The purpose of this post is to initiate a new discussion thread on this policy recommendation for the March House of Delegates. To advocate that pharmacists provide leadership in caring for patients receiving medications for anticoagulant therapy management; further To advocate that pharmacists be responsible for coordinating the individualized care of patients receiving medications for anticoagulation therapy management; further, To encourage pharmacists who participate in anticoagulation therapy management to educate patients, caregivers, prescribers, and other members of the interprofessional healthcare team about anticoagulant medication uses, drug interactions, adverse effects, the importance of adhering to therapy, access to care, and recommended laboratory testing and other monitoring. (Note: This policy would supersede ASHP policy 0816.) --------------------------------------------------- The policy language above has been approved by the Council on Therapeutics but not by the ASHP Board of Directors or the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Wednesday, March 1, 2017
March vHOD COT 3: Drug Dosing in Diseases That Modify Pharmacokinetics or P 0 W. O'Hara The purpose of this post is to initiate a new discussion thread on this policy recommendation for the March House of Delegates. To encourage research on the pharmacokinetics and pharmacodynamics of drugs in acute and chronic disease states; further, To support development and use of standardized models, laboratory assessment, genomic testing, utilization biomarkers, and systemwide documentation of pharmacokinetic and pharmacodynamic changes in acute and chronic disease states; further, To collaborate with stakeholders in enhancing aggregation and publication of and access to data on the effects of such pharmacokinetic and pharmacodynamic changes on drug dosing within these patient populations. --------------------------------------------------- The policy language above has been approved by the Council on Therapeutics but not by the ASHP Board of Directors or the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Wednesday, March 1, 2017
March vHOD CPuP 3: Collaborative Drug Therapy Management 0 W. O'Hara The purpose of this post is to initiate a new discussion thread on this policy recommendation for the March House of Delegates. To pursue the development of federal and state laws and regulations that authorize collaborative drug therapy management by pharmacists; further, To advocate expansion of federal and state laws and regulations that optimize pharmacists’ ability to provide the full range of professional services within their scope of expertise; further, To advocate for state laws and regulations that would allow pharmacists to transmit prescriptions electronically under collaborative drug therapy management protocols; further, To acknowledge that as part of these advanced collaborative practices, pharmacists, as active members in team-based care, must be responsible and accountable for medication‐related outcomes; further, To support affiliated state societies in the pursuit of state-level collaborative drug therapy management authority for pharmacists. (Note: This policy would supersede ASHP policy 1217.) -------------------------------------------------- The policy language above has been approved by the Council on Public Policy but not by the ASHP Board of Directors or the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Wednesday, March 1, 2017
March vHOD CPM 4: Ensuring Patient Safety and Data Integrity During Cyberat 0 W. O'Hara The purpose of this post is to initiate a new discussion thread on this policy recommendation for the March House of Delegates. To advocate that healthcare organizations include pharmacists in (a) assessing cyber-security systems and procedures for vulnerabilities, (b) implementing cyber-security strategies, and (c) reviewing cyber-security breaches and developing corrective actions; further, To encourage the development of business continuity plans by pharmacy departments; further, To advocate that healthcare organizations assess vendor systems to validate the security and integrity of data, including an assessment of the minimum amount of patient health information vendors require to provide services. --------------------------------------------------- The policy language above has been approved by the Council on Pharmacy Management but not by the ASHP Board of Directors or the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Wednesday, March 1, 2017
March vHOD CPhP1: Reduction of Unused Prescription Drug Products 0 W. O'Hara The purpose of this post is to initiate a new discussion thread on this policy recommendation for the March House of Delegates. To recognize that unused prescription drug products contribute to drug misuse, abuse, and diversion; further, To advocate for research, education, and best practices to ensure appropriate quantities of prescription drug products are prescribed, including but not limited to partial fills or refills; further, To advocate that pharmacists take a leadership role in reducing excess quantities of unused prescription drug products. -------------------------------------------------- The policy language above has been approved by the Council on Pharmacy Practice but not by the ASHP Board of Directors or the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Wednesday, March 1, 2017
June HOD CPhP 1. Automated Preparation and Dispensing Technology for Steril 2 W. O'Hara I am concerned that we (ASHP) are not using stronger language than “advocate that health systems adopt automation and information technology for preparing and dispensing sterile preparations”. This is a critical medication safety issue that can be significantly improved by one of the simplest and most trusted pharmacy technologies – barcode scanning, which is a foundational strategy of every workflow software program on the market. The ASHP statement on barcode verification during inventory, preparation, and dispensing of medications, which was adopted in 2010, takes into account the need for IV compounding ingredient barcode verification. “Compounded medications (e.g. sterile preparations) are often labeled by the pharmacy with a bar code that references a prescription or order number that describes the intended contents of the prescribed dose but provides no assurance that the prescribed contents were actually used in the product’s preparation……. Scanning of source ingredients during compounding, repackaging, or labeling processes can ensure that labeled doses contain the appropriate ingredients.”We seem to be treating this gap in our IV medication preparation and dispensing processes as if it were new problem with untested solutions that require extensive research. There are enough reports and papers that all align on the safety benefits of IV workflow software that use barcode ingredient verification that we should take a more assertive position on their use. Here is a sample of publications that demonstrate similar and concrete benefits of IV compounding barcode ingredient verification software:• Speth, S, "Optimizing i.v. workflow". Am J Health Syst Pharm December 1, 2013 70:2076-2080• Hingle, J, Deng, Y, Lin, J. "Reducing Compounding Errors at a Pediatric Hospital", Pharmacy Purchasing and Products, May, 2013• Moniz, T, Chu, S, Tom, C, Lutz, P, Arnold, A, Gura, K, Patterson, A, "Sterile product compounding using an i.v. compounding workflow management system at a pediatric hospital", Am J Health-Syst Pharm. 2014; 71:1311-7• Reece, KM, Lozano, MA, Roux, MS, Spivey, SM. "Implementation and evaluation of a gravimetric i.v. workflow software system in an oncology ambulatory care pharmacy". Am J Health-Syst Pharm. 2016; 73:165–173Best regards,John Barickman, RPh, MBA
by J. Barickman
Wednesday, June 8, 2016
June HOD CPhP 2. Integrated Approach for the Pharmacy Enterprise 1 W. O'Hara On behalf of the Council for Pharmacy Practice, we met to discuss the proposed amendment.  We are supportive of the amendment as written.  To further support the recommended language we recommend  changes to the rationale to ensure the reader understands the terminology of “pharmacy enterprise” and what that encompasses.  During policy week we wanted to ensure that with expanding health care systems we recognized that the enterprise not only included also pharmacists that may function under other service lines across the system as well (reporting to a medical service or perhaps laboratory service like in pharmacogenomics).  The proposed amendment before the HOD would be as follows: To advocate that pharmacy department leaders promote an integrated  approach for all pharmacy personnel  involved in the medication-use process; further,   To advocate a high level of coordination of all components of the pharmacy enterprise across the continuum of care for the purpose of optimizing (1) medication-use safety, (2) quality, (3) outcomes, and (4)   drug therapy; further, The Council will work together with Dr. Scott Knoer to bring the amendment before the House at the June 2016 meeting.  Thank you in advance ------------------------------ Julie Groppi FASHP Chair, ASHP Council for Pharmacy Practice 2015-16
by B. O'Hara
Wednesday, May 25, 2016
June HOD CPhP 3. Preventing Exposure to Allergens 1 W. O'Hara Latest update from ASHP COnnectOn behalf of the Council for Pharmacy Practice, we met to discuss the recommendations and amending language brought forth by Dr. Kristi Gullickson, Dr. Casey White, Dr. Arlene Iglar and Mr. Jamie Sinclair. Council members agreed in concept with the amending language but recommended a different term could be used rather than “solicitation”. In working with the delegates we agreed on replacing the terminology of "solicitation" with "collection". When the Council initially crafted the language for this policy statement, we intended that “assessment and documentation” to include the act of the obtaining the initial list and/or verifying the final list of allergens from the patient but agree that adding the language of "collection" helps to clarify the intent. In addition, we are in agreement regarding the need for education of all pharmacy staff to include pharmacists and pharmacy technicians. We initially intended the term "professional" to encompass the pharmacy technician but realize that the broader term of "personnel" is more readily understood to include technicians. The amending policy before the HOD would be as follows: To advocate for pharmacy participation in the collection, assessment and documentation of a complete list of allergens pertinent to medication therapy, including food, excipients, medications, devices, and supplies, and any other relevant personal or environmental factor, for the purpose of clinical decision-making; further, To advocate that vendors of medication-related databases incorporate and maintain information about medication-related allergens and cross-sensitivities; further, To advocate that pharmacy professional personnel actively review allergens pertinent to medication therapy and minimize patient and healthcare worker exposure to known allergens, as feasible; further, To encourage pharmacist pharmacy personnel education on medication-related allergens.The Council is supportive of the proposed amendment and language changes. Thank you for the careful consideration of this policy recommendation. ------------------------------Julie Groppi PharmD, FASHPChair, Council for Pharmacy Practice 2015-16
by B. O'Hara
Wednesday, May 25, 2016
June HOD COT 5. Use of Methadone to Treat Pain 0 W. O'Hara To acknowledge that methadone has a role in pain management and that its pharmacologic properties present unique risks to patients; further,  To oppose the use of methadone as a preferred treatment option for acute and chronic pain; further,  To advocate that all healthcare practitioners who prescribe or dispense methadone complete a standardized educational program specific to the drug; further,  To advocate that pain management experts, payers, and manufacturers collaborate to provide educational programs for healthcare professionals on treating acute and chronic pain with opioids, including methadone; further,  To advocate that all facilities that dispense methadone, including addiction treatment programs, participate in state prescription drug monitoring programs. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 6. Therapeutic Indication of Prescribing 0 W. O'Hara To advocate that healthcare organizations optimize use of clinical decision support systems by structuring them to include the indication for high-risk and problem-prone medications. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 1. Stewardship of Drugs with Potential for Abuse 0 W. O'Hara To encourage stewardship of drugs with potential for abuse; further,  To facilitate the development of best practices for prescription drug monitoring programs and drug take-back disposal programs for drugs with potential for abuse.  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy." ------------------------------ Amber J Lucas, PharmD, BCPS, FASHP Clinical Pharmacist Olathe Medical Center 20333 W. 151st St. Olathe, KS 66061 913-791-4287 ------------------------------
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 2. Appropriate Use of Antipsychotic Drug Therapies 0 W. O'Hara   To advocate for the documentation of appropriate indication and goals of therapy to promote the judicious use of antipsychotic drugs and reduce the potential for harm; further,  To support the participation of pharmacists in the management of antipsychotic drug use, which is an interdisciplinary, collaborative process for selecting appropriate drug therapies, educating and monitoring patients, continually assessing outcomes of therapy, and identifying appropriate discontinuation; further, To advocate that pharmacists lead efforts to prevent inappropriate use of antipsychotic drugs, including engaging in strategies to detect and address patterns of use in patient populations at increased risk for adverse outcomes. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD COT 3. Safety of Epidural Steroid Injections 0 W. O'Hara To encourage healthcare providers to 1) inform patients about the significant risks associated with epidural steroid injections, and 2) request their informed consent; further,  To encourage healthcare organizations to prevent adverse events related to epidural steroid injections by having pharmacists involved in the development of protocols that promote the safe use of such injections.  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."  
by W. O'Hara
Sunday, May 15, 2016
June HOD CEWD 3. Developing Leadership Competencies 0 W. O'Hara To work with healthcare organization leadership to foster opportunities, allocate time, and provide resources for pharmacy practitioners to move into leadership roles; further,  To encourage leaders to seek out and mentor pharmacy practitioners in developing administrative, managerial, and leadership skills; further,  To encourage pharmacy practitioners to obtain the skills necessary to pursue administrative, managerial, and leadership roles; further,  To encourage colleges of pharmacy and ASHP state affiliates to collaborate in fostering student leadership skills through development of co-curricular leadership opportunities, leadership conferences, and other leadership promotion programs; further,  To reaffirm that residency programs should develop leadership skills through mentoring, training, and leadership opportunities; further,  To foster leadership skills for pharmacists to use on a daily basis in their roles as leaders in patient care.  (Note: This policy would supersede ASHP policy 1518.)  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CEWD 5. Cultural Competency and Cultural Diversity 0 W. O'Hara To endorse the development of cultural competency of pharmacy educators, practitioners, residents, students, and technicians; further,  To educate providers on the importance of providing culturally congruent care to achieve quality care and patient engagement; further,  To advocate for an ethnically and culturally diverse workforce.  (Note: This policy would supersede ASHP policy 1414.)  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 1. Controlled Substance Diversion and Patient Access 0 W. O'Hara To enhance awareness by pharmacists, healthcare providers, and the public of drug diversion and abuse of controlled substances; further,  To advocate that pharmacists take a leadership role in national efforts to reduce the incidence of controlled substance abuse; further,  To advocate that pharmacists lead collaborative efforts by organizations of healthcare professionals, patient advocacy organizations, and regulatory authorities to develop and promote best practices for preventing drug diversion and appropriately using controlled substances to optimize patient access and therapeutic outcomes; further,  To advocate that the Drug Enforcement Administration and other regulatory authorities interpret and enforce laws, rules, and regulations to support patient access to appropriate therapies, minimize burdens on pharmacy practice, and provide reasonable safeguards against fraud, misuse, abuse, and diversion of controlled substances; further,  To encourage healthcare organizations to establish programs to support patients and personnel with substance abuse and dependency issues. --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 4. Patient Satisfaction 0 W. O'Hara To encourage pharmacists to evaluate their practice settings for opportunities to improve the level of satisfaction patients have with healthcare services and with the outcomes of their drug therapy; further, To educate pharmacists and pharmacy personnel about the relationship between patient satisfaction and positive health outcomes, further, To develop or adopt tools that will (1) provide a system for monitoring trends in the quality of pharmacy services to patients, (2) increase recognition of the value of pharmacy services, and (3) provide a basis for making improvements in the process and outcomes of pharmacy services in efforts to engage patients and improve satisfaction; further, To facilitate a dialogue with and education of national patient satisfaction database vendors on the role and value of clinical pharmacy services. (Note: This policy would supersede ASHP policy 0104.) --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 3. Pharmaceutical Distribution Systems 0 W. O'Hara To support wholesaler/distribution business models that meet the requirements of hospitals and health systems with respect to timely delivery of products, minimizing short-term outages and long-term product shortages, managing and responding to product recalls, fostering product-handling and transaction efficiency, preserving the integrity of products as they move through the supply chain, and maintaining affordable service costs. To encourage wholesalers and other trading partners in the drug supply chain to implement policies and procedures consistent with United States Pharmacopeia (USP) Chapter 800 to mitigate the risk of exposure as hazardous drug products move through the supply chain. (Note: This policy would supersede ASHP policy 1016.) --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy." -
by W. O'Hara
Sunday, May 15, 2016
June HOD CPM 2. Surface Contamination on Packages and Vials of Hazardous Dr 0 W. O'Hara To advocate that pharmaceutical manufacturers eliminate surface contamination on packages and vials of hazardous drugs; further, To inform pharmacists and other personnel of the potential presence of surface contamination on the packages and vials of hazardous drugs; further, To advocate that the Food and Drug Administration require standardized labeling and package design for hazardous drugs that would alert handlers to the potential presence of surface contamination; further, To encourage healthcare organizations to adhere to published standards and regulations to protect workers from undue exposure to hazardous drugs.  (Note: This policy would supersede ASHP policy 0618.) --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
June HOD CEWD 2. Career Opportunities for Pharmacy Technicians 0 W. O'Hara To promote the image of pharmacy technicians as valuable contributors to healthcare delivery; further,  To develop and disseminate information about career opportunities that enhances the recruitment and retention of qualified pharmacy technicians; further,  To support pharmacy technician career advancement opportunities, commensurate with training and education; further,  To encourage compensation models for pharmacy technicians that provide a living wage.  (Note: This policy would supersede ASHP policy 0211.)  --------------------------------------------------- The policy language above has been approved by the ASHP Board of Directors but not by the ASHP House of Delegates and is therefore not final ASHP policy. The policy language has been provided for review and discussion purposes only and may not be reproduced, circulated, or quoted without an express and prominent statement on the document that reads: "This is not final approved ASHP policy."
by W. O'Hara
Sunday, May 15, 2016
Membership Management Software Powered by YourMembership  ::  Legal